Evidence atlas · Topic

Palliative carewhat the research examines

Short answer: The library holds 15 references on virtual reality and palliative care, published between 2019 and 2024. They include 3 systematic reviews or meta-analyses and 1 randomised controlled trial. The research mainly examines symptoms such as pain, anxiety, breathlessness and well-being in patients receiving palliative care and in oncology.

The evidence in numbers

15References
3Systematic reviews and meta-analyses
1Randomised trials
2019–2024Years
  • Meta-analyses1
  • Systematic reviews2
  • Randomised controlled trials1
  • Non-randomised clinical studies2
  • Pilot or feasibility studies5
  • Qualitative or user studies1
  • Narrative or scoping reviews1
  • Essays, editorials or conceptual papers1
  • Study protocols1

Counted in the RVer study library · languages: Portuguese, English. The design of each study was classified by the team from the publication.

What the research examines

  • Symptoms such as pain, anxiety, breathlessness and well-being in patients receiving palliative care and in oncology.
  • Whether virtual reality is feasible and acceptable for bedbound or very tired patients.
  • Personalised content: going back to places that mean something to the person.
  • Support for family members and carers.

What is not yet known

  • Few randomised trials; most are small feasibility or pre-post studies.
  • What happens to symptoms after the session, and with repeated sessions.
  • Which content and which duration best suit each stage of the illness.

The references, by study design

Meta-analyses · 1

Systematic reviews · 2

Pilot or feasibility studies · 5

Qualitative or user studies · 1

Narrative or scoping reviews · 1

Essays, editorials or conceptual papers · 1

Glossary terms

Other topics

This page describes what published research on virtual reality examines in this topic. It is not a claim about RVer's performance and does not replace clinical assessment. The Class I medical device registration (EUDAMED, Basic UDI-DI 56006195127RVERTZ, and INFARMED, Portugal, CDM 94571546) covers the RVer base product.